CoQ10 lowers muscle-damage markers in the blood, and more seems to do more

Hard training damages muscle, and that damage shows up in the blood as enzymes and proteins such as creatine kinase, lactate dehydrogenase and myoglobin, alongside markers of oxidative stress like malondialdehyde. Coenzyme Q10 has long been studied for its potential to soften this exercise-induced damage and the oxidative stress that accompanies it. Individual trials have been small and scattered, so it has been hard to say whether supplementation actually moves these markers, and harder still to say whether the dose matters. This review pooled the trial evidence to answer both questions.

The researchers searched PubMed, Scopus and Web of Science up to August 2023 for randomised controlled trials testing coenzyme Q10 against control for markers of exercise-induced muscle damage, physical performance and oxidative stress in adults. Twenty-eight trials met the criteria, covering 830 people in total. Results were pooled using a random-effects model, and the team ran a dose-response analysis to test whether higher daily doses produced larger changes. The certainty of the evidence was formally graded.

Supplementation significantly lowered creatine kinase by 50.64 IU/L on average, lactate dehydrogenase by 52.10 IU/L, myoglobin by 21.77 ng/ml and malondialdehyde, a marker of oxidative stress, by 0.73 µmol/l. Each additional 100 mg per day was linked to further reductions in all four markers. Total antioxidant capacity, by contrast, did not change significantly. In standardised terms the effect on lactate dehydrogenase was rated very large and the effects on creatine kinase and malondialdehyde moderate, while other outcomes were not significant.

This is the most comprehensive pooling of coenzyme Q10 trials on exercise recovery markers to date, and it turns a scattered literature into a fairly consistent signal on blood chemistry. What it does not show is any effect a lifter or runner would actually notice: the results describe biomarker changes, not reduced soreness, faster strength recovery or improved performance. How closely those markers track real recovery remains an open question. The authors also caution that most trials came from Asia, which limits how confidently the findings generalise, and they call for larger and longer trials in other populations.

If you take coenzyme Q10 hoping it blunts the damage of hard sessions, this pooled evidence suggests it does move the relevant blood markers in the direction you would want, and larger daily amounts moved them further in these trials. Whether that translates into feeling fresher, recovering faster or performing better is simply not answered here; a marker changing is not the same as a benefit you can feel. This is a reason to watch the evidence develop rather than proof of a recovery edge.